Forvis Mazars Wealth Advisors’s AstraZeneca AZN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$455K Buy
+2,306
New +$445K 0.01% 295
2025
Q4
Sell
-1,442
Closed -$221K 407
2025
Q3
$221K Buy
+1,442
New +$218K ﹤0.01% 388
2025
Q2
Sell
-1,431
Closed -$210K 398
2025
Q1
$210K Buy
+1,431
New +$207K 0.01% 379
2024
Q4
Sell
-1,528
Closed -$238K 420
2024
Q3
$238K Sell
1,528
-58
-4% -$9.36K 0.01% 408
2024
Q2
$247K Hold
1,586
0.01% 377
2024
Q1
$215K Buy
1,586
+71
+5% +$9.4K 0.01% 378
2023
Q4
$204K Sell
1,515
-86
-5% -$11.2K 0.01% 375
2023
Q3
$217K Sell
1,601
-266
-14% -$36.3K 0.01% 367
2023
Q2
$267K Buy
1,867
+326
+21% +$48K 0.01% 370
2023
Q1
$214K Buy
1,541
+16
+1% +$2.15K 0.01% 383
2022
Q4
$207K Buy
+1,525
New +$191K 0.01% 375
2022
Q3
Sell
-2,000
Closed -$264K 385
2022
Q2
$264K Buy
2,000
+153
+8% +$20.1K 0.01% 338
2022
Q1
$245K Sell
1,847
-1,077
-37% -$129K 0.01% 269
2021
Q4
$341K Sell
2,924
-1,589
-35% -$187K 0.01% 213
2021
Q3
$542K Buy
+4,513
New +$525K 0.02% 174

Other funds holding AZN

Forvis Mazars Wealth Advisors's AZN Position: Q1 2026 in Review

Forvis Mazars Wealth Advisors opened a new position in AstraZeneca (AZN) in Q1 2026: 2,306 shares worth $455K. The stake represents 0.01% of the portfolio and ranks #295 among its holdings. This is a return to the name: Forvis Mazars Wealth Advisors previously reported a position in AZN as recently as Q3 2025.

Forvis Mazars Wealth Advisors first reported a position in AZN in Q3 2021 and has held it in 15 quarters since. The position peaked at $542K in Q3 2021. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

  • Forvis Mazars Wealth Advisors held 2,306 shares of AstraZeneca worth $455K as of Q1 2026.
  • AstraZeneca was a new Forvis Mazars Wealth Advisors position in Q1 2026.
  • AstraZeneca made up 0.01% of Forvis Mazars Wealth Advisors's portfolio in Q1 2026, its #295 holding.
  • Forvis Mazars Wealth Advisors first reported a position in AstraZeneca in Q3 2021 and has held it in 15 quarters since.
  • Forvis Mazars Wealth Advisors's AstraZeneca position peaked at $542K in Q3 2021.
  • 1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Forvis Mazars Wealth Advisors's 13F filing for Q1 2026, filed 1 May 2026.